Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), headquartered at Chengdu, Sichuan Province of China, is a leading developer, manufacturer and supplier of patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective National Medical Reimbursement List (NMRL) and 7 are listed in the Essential Drug List (EDL) of China. Our pipeline consists of 10 late stage product candidates pending the approval by State Food and Drug Administration (SFDA) in China.